Type 1 diabetes mellitus is a multifactorial disease resulting from immune-mediated or idiopathic destruction of pancreatic β cells, leading to absolute insulin deficiency.1
The original investigational product BCD-253 is a monoclonal antibody.
A monoclonal antibody is a protein created by scientists in the laboratory, which is equivalent to natural immune system antibodies and designed to bind to a specific target in the human body [].2
BCD-253 is one of the medicinal products in BIOCAD’s clinical development program.
- I.I. Dedov, M.V. Shestakova. Type 1 diabetes mellitus in adults. Clinical recommendations. Public organization "Russian Association of Endocrinologists". 2019.
- Breedveld FC. Therapeutic monoclonal antibodies. The Lancet. 2000;355(9205):735–40.
This website section contains information about an unauthorized investigational medicinal product for medical use.